Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003)

Diagnostic Microbiology and Infectious Disease
Ronald N JonesHelio S Sader

Abstract

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme was initiated in 1997 (1999 for the United States). This program monitors resistance in participant medical centers where carbapenems are prescribed and drug use data can be obtained. An earlier report found antimicrobial use was not a clear cause of local or aggregate changes in resistance rates. This study addresses the role of dissemination of resistant clones on susceptibility rates for nonfermentors, Acinetobacter spp. (ACB) and Pseudomonas aeruginosa (PSA). Carbapenem (CARB)-multidrug-resistant strains (MDR) from among 236 ACB and 1,111 PSA were tested by reference broth microdilution methods, automated ribotyping, and pulsed field gel electrophoresis to determine possible clonal dissemination. Each strain was also tested for metallo-beta-lactamases (MbetaL) (phenotypic and polymerase chain reaction); and then analyzed by CARB-R rate and defined daily dose (DDD)/100 days use groupings (high, moderate, and low). For the aggregate 15 sites in the MYSTIC Programme each year, the CARB-resistant rate decreased over 5 years; but other drug-resistance rates generally escalated. Changes were not related to antimicrobial use calculations. The discov...Continue Reading

References

Jun 1, 1995·Antimicrobial Agents and Chemotherapy·K BushA A Medeiros
Feb 1, 1997·Antimicrobial Agents and Chemotherapy·B A Rasmussen, K Bush
Dec 14, 1999·International Journal of Antimicrobial Agents·P J TurnerJ McKellar
Sep 2, 2000·The Journal of Antimicrobial Chemotherapy·P J Turner
Jan 5, 2002·Diagnostic Microbiology and Infectious Disease·M A PfallerUNKNOWN MYSTIC Program Study Group
May 16, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A S Levin
Aug 1, 2002·Journal of Clinical Microbiology·Timothy R WalshAna Gales
May 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carl UrbanJames J Rahal
Jan 9, 2004·The Journal of Antimicrobial Chemotherapy·Alan H MutnickRonald N Jones

❮ Previous
Next ❯

Citations

Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emil LeshoDavid Craft
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ronald N JonesPaul R Rhomberg
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Apr 16, 2005·Clinical Microbiology Reviews·Timothy R WalshPatrice Nordmann
Oct 7, 2005·Journal of Clinical Microbiology·Preeti PancholiPhyllis Della Latta
Dec 20, 2011·PloS One·Scott A WeisenbergKyu Y Rhee
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lisa L Maragakis, Trish M Perl
Sep 25, 2007·Diagnostic Microbiology and Infectious Disease·Volkan KortenUNKNOWN Turkish MYSTIC Study Group
Jul 31, 2007·Diagnostic Microbiology and Infectious Disease·Paul R RhombergRonald N Jones
Dec 29, 2004·International Journal of Antimicrobial Agents·Helio S SaderRonald N Jones
Dec 20, 2005·Diagnostic Microbiology and Infectious Disease·Serhat Unal, Jose Angel Garcia-Rodriguez
Sep 15, 2005·Enfermedades infecciosas y microbiología clínica·Caio Marcio Figueiredo-MendesCarlos Roberto Veiga-Kiffer
Nov 18, 2017·Annals of Clinical Microbiology and Antimicrobials·Kevin M RaibleSuresh G Joshi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.